Over 90 Total Lots Up For Auction at One Location - WA 04/08

A point about how reimbursement impacts care

August 22, 2013
Don Morris
From the August 2013 issue of HealthCare Business News magazine
By Don Morris

“Humungous tonsils” was the verdict of the pediatrician who sent us off to see two ENT specialists with our twins. The first doctor explained that they were indeed humungous and that any tonsils larger than a certain size should be removed or they could lead to poor functioning at school, among other problems. He would be happy to schedule the surgery. The case seemed clear. But the second doctor needed to know more to make a decision: Were the twins tired and cranky in the morning? Did they breathe irregularly in their sleep? Could we send a video?

What happened here illustrates a point about how reimbursement impacts care, that I think is often missed amid dire forecasts that health care reform will lead to “cookie-cutter” medicine. It’s actually the other way around. The current fee-for-service system, represented by doctor number one, rewards a one-size-fits-all approach that increases volume; simple guidelines (e.g., the tonsil size rule) have been developed to make decisions easy so providers can focus their time on providing the reimbursed treatments. The second doctor, a salaried professor who had no financial interest, was much more thoughtful about her decision. As health care reform begins to make medical groups financially accountable for patients’ outcomes ranging from hospital readmissions to heart attacks, the industry is scrambling to collect individual health data and develop a new generation of analytics that that is focused on better understanding of impact of medical decisions on individuals. Because bad outcomes like readmissions will be penalized, and good outcomes will be rewarded, simple economics are driving the industry to personalized care.

Most medical decisions involve a tradeoff of risks of potentially fatal outcomes: a CT scan of your coronary arteries may help diagnose heart disease but could cause cancer; aspirin and other blood thinners reduce your risk of heart disease but could lead to serious bleeding. Simple cookie-cutter guidelines fail to take individual complexity into account, often recommending treatment to people who could on balance be harmed, or fail to recommend treatments to people who would benefit.

Before evidence-based medicine, medical decisions were all personalized, but because physicians didn’t have access to analytic evidence their decisions were based on intuition, or a limited number of personal experiences. Since that era, clinical trials have created a sound scientific foundation for decisions= and for national care guidelines, but the simplicity of these guidelines has led to less personalization of decisions. Now we’ve moved to a stage where there’s enough clinical evidence, analytic horsepower, and patient data in electronic records to guide medical decisions that are both personalized and evidence-based.

You Must Be Logged In To Post A Comment